- Home
- GOSS vs TVGN Comparison
GOSS vs TVGN Comparison
Compare GOSS & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- TVGN
- Stock Information
- Founded
- GOSS 2015
- TVGN 2020
- Country
- GOSS United States
- TVGN United States
- Employees
- GOSS N/A
- TVGN N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- TVGN Blank Checks
- Sector
- GOSS Health Care
- TVGN Finance
- Exchange
- GOSS Nasdaq
- TVGN Nasdaq
- Market Cap
- GOSS 212.8M
- TVGN 222.3M
- IPO Year
- GOSS 2019
- TVGN N/A
- Fundamental
- Price
- GOSS $1.27
- TVGN $1.23
- Analyst Decision
- GOSS Strong Buy
- TVGN Strong Buy
- Analyst Count
- GOSS 5
- TVGN 1
- Target Price
- GOSS $9.20
- TVGN $10.00
- AVG Volume (30 Days)
- GOSS 1.5M
- TVGN 537.1K
- Earning Date
- GOSS 03-13-2025
- TVGN 04-08-2025
- Dividend Yield
- GOSS N/A
- TVGN N/A
- EPS Growth
- GOSS N/A
- TVGN N/A
- EPS
- GOSS N/A
- TVGN N/A
- Revenue
- GOSS $114,701,000.00
- TVGN N/A
- Revenue This Year
- GOSS N/A
- TVGN N/A
- Revenue Next Year
- GOSS $154.71
- TVGN N/A
- P/E Ratio
- GOSS N/A
- TVGN N/A
- Revenue Growth
- GOSS N/A
- TVGN N/A
- 52 Week Low
- GOSS $0.50
- TVGN $0.26
- 52 Week High
- GOSS $1.55
- TVGN $4.78
- Technical
- Relative Strength Index (RSI)
- GOSS 51.40
- TVGN 50.23
- Support Level
- GOSS $1.27
- TVGN $1.11
- Resistance Level
- GOSS $1.48
- TVGN $1.21
- Average True Range (ATR)
- GOSS 0.11
- TVGN 0.08
- MACD
- GOSS -0.01
- TVGN 0.02
- Stochastic Oscillator
- GOSS 51.90
- TVGN 91.30
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.